NO177793C - Fremgangsmåte for fremstilling av et fusjonsprotein, samt nukleinsyre, ekspresjonsvektor og vertscelle som kan anvendes ved fremgangsmåten - Google Patents

Fremgangsmåte for fremstilling av et fusjonsprotein, samt nukleinsyre, ekspresjonsvektor og vertscelle som kan anvendes ved fremgangsmåten

Info

Publication number
NO177793C
NO177793C NO882917A NO882917A NO177793C NO 177793 C NO177793 C NO 177793C NO 882917 A NO882917 A NO 882917A NO 882917 A NO882917 A NO 882917A NO 177793 C NO177793 C NO 177793C
Authority
NO
Norway
Prior art keywords
preparation
nucleic acid
well
host cell
fusion protein
Prior art date
Application number
NO882917A
Other languages
English (en)
Other versions
NO882917L (no
NO177793B (no
NO882917D0 (no
Inventor
Alan John Kingsman
Susan Mary Kingsman
Sally Elizabeth Adams
Michael Henry Malim
Elizabeth-Jane Claire Mellor
Original Assignee
British Bio Technology
Oxford Gene Systems Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB868626148A external-priority patent/GB8626148D0/en
Priority claimed from GB878708531A external-priority patent/GB8708531D0/en
Priority claimed from US07/036,807 external-priority patent/US5041385A/en
Application filed by British Bio Technology, Oxford Gene Systems Ltd filed Critical British Bio Technology
Publication of NO882917D0 publication Critical patent/NO882917D0/no
Publication of NO882917L publication Critical patent/NO882917L/no
Publication of NO177793B publication Critical patent/NO177793B/no
Publication of NO177793C publication Critical patent/NO177793C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO882917A 1986-11-01 1988-06-30 Fremgangsmåte for fremstilling av et fusjonsprotein, samt nukleinsyre, ekspresjonsvektor og vertscelle som kan anvendes ved fremgangsmåten NO177793C (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB868626148A GB8626148D0 (en) 1986-11-01 1986-11-01 Antigen presentation & purification system
GB878708531A GB8708531D0 (en) 1987-04-09 1987-04-09 Fusion proteins & particles
US07/036,807 US5041385A (en) 1986-11-01 1987-04-10 Vector expressing fusion proteins and particles
PCT/GB1987/000764 WO1988003563A1 (en) 1986-11-01 1987-10-28 Fusion proteins and particles

Publications (4)

Publication Number Publication Date
NO882917D0 NO882917D0 (no) 1988-06-30
NO882917L NO882917L (no) 1988-08-29
NO177793B NO177793B (no) 1995-08-14
NO177793C true NO177793C (no) 1995-11-22

Family

ID=27263194

Family Applications (1)

Application Number Title Priority Date Filing Date
NO882917A NO177793C (no) 1986-11-01 1988-06-30 Fremgangsmåte for fremstilling av et fusjonsprotein, samt nukleinsyre, ekspresjonsvektor og vertscelle som kan anvendes ved fremgangsmåten

Country Status (8)

Country Link
EP (1) EP0330661B1 (no)
JP (2) JP2708046B2 (no)
AU (1) AU606896B2 (no)
CA (1) CA1339263C (no)
DE (1) DE3788807T2 (no)
ES (1) ES2010231A6 (no)
NO (1) NO177793C (no)
WO (1) WO1988003563A1 (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0329671B1 (en) * 1986-11-01 1994-01-12 British Bio-Technology Limited Particulate hybrid hiv antigens
US5614404A (en) * 1988-06-10 1997-03-25 Theriod Biologics, Incorporated Self-assembled, defective, non-self-propagating lentivirus particles
US5631154A (en) * 1988-06-10 1997-05-20 Therion Biologics, Incorporated Self assembled, defective, non-self-propagating lentivirus particles
US5747324A (en) * 1988-06-10 1998-05-05 Therion Biologics Corporation Self-assembled, defective, non-self-propagating lentivirus particles
AU4665389A (en) * 1988-11-23 1990-06-12 Regents Of The University Of California, The Position-specific insertion vectors and method of using same
JPH04500308A (ja) * 1989-05-17 1992-01-23 リサーチ・コーポレーション・テクノロジーズ・インコーポレーテッド 組換え型生成物のレトロウィルス媒介分泌
EP0474868B1 (en) * 1989-05-30 1996-11-13 Nippon Zeon Co., Ltd. Method of producing core structure of retro virus and particle produced thereby
JP3034025B2 (ja) * 1989-06-01 2000-04-17 アプライド・バイオテクノロジー・インコーポレーテツド 自己アセンブルド欠損非自己増殖性ウイルス粒子
WO1991019803A1 (en) * 1990-06-19 1991-12-26 Applied Biotechnology, Incorporated Self assembled, defective, nonself-propagating viral particles
GB9107631D0 (en) * 1991-04-10 1991-05-29 British Bio Technology Proteinaceous particles
GB9223084D0 (en) * 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
FR2703996B1 (fr) * 1993-04-16 1995-07-21 Transgene Sa Ensemble de transposition destine au transfert d'un gene d'interet dans le genome d'une cellule eucaryote.
US7476517B2 (en) 1999-06-30 2009-01-13 Evotec Ag Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
US20040014033A1 (en) 1999-06-30 2004-01-22 Evotec Biosystems Ag, A Corporation Of Germany Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
DE60034947T2 (de) * 1999-06-30 2008-01-24 Evotec Ag Virusähnliche partikel, vorbereitung und verwendung in screening und funktionelle genomanwendung
EP1219705B1 (en) * 2000-12-29 2007-11-28 Evotec AG Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
FI116198B (fi) 2001-07-16 2005-10-14 Valtion Teknillinen Polypeptidien immobilisointimenetelmä
LT5414B (lt) 2005-04-13 2007-04-25 Biotechnologijos Institutas Monokloninių antikūnų gavimo būdas, hibridomos, gautos šiuo būdu ir rekombinantinės chimerinės į virusus panašios dalelės su įterptais kitų baltymų fragmentais kaip imunogenai hibridomų gavimui šiuo būdu

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8324800D0 (en) * 1983-09-15 1983-10-19 Pasteur Institut Antigens
JPS6193199A (ja) * 1984-10-13 1986-05-12 Kyowa Hakko Kogyo Co Ltd 抗インタ−フエロン−γモノクロ−ナル抗体

Also Published As

Publication number Publication date
ES2010231A6 (es) 1989-11-01
AU8105787A (en) 1988-06-01
NO882917L (no) 1988-08-29
DE3788807D1 (de) 1994-02-24
JP2708046B2 (ja) 1998-02-04
JPH09248191A (ja) 1997-09-22
NO177793B (no) 1995-08-14
NO882917D0 (no) 1988-06-30
EP0330661A1 (en) 1989-09-06
WO1988003563A1 (en) 1988-05-19
AU606896B2 (en) 1991-02-21
EP0330661B1 (en) 1994-01-12
DE3788807T2 (de) 1994-06-30
JPH02501026A (ja) 1990-04-12
CA1339263C (en) 1997-08-12

Similar Documents

Publication Publication Date Title
NO177793C (no) Fremgangsmåte for fremstilling av et fusjonsprotein, samt nukleinsyre, ekspresjonsvektor og vertscelle som kan anvendes ved fremgangsmåten
NO177794C (no) Fremgangsmåte for fremstilling av et fusjonsprotein, samt nukleinsyre, ekspresjonsvektor og vertscelle som kan anvendes ved fremgangsmåten
NO175715C (no) Analogifremgangsmåte ved fremstilling av terapeutisk aktive aminosyrederivater, samt mellomprodukter ved fremstilling av disse
DK110885A (da) Nucleinsyre-proteinkonjugater, disses anvendelse samt fremgangsmaade til fremstilling heraf
IT7921838A0 (it) Processo di rivelazione e di caratterizzazione di un acido nucleico o di una sua sequenza e reattivo enzimatico per la realizzazione di questo processo.
NO871785L (no) Fremgangsmaate for fremstilling av et proteinprodukt samt vektorsystem for fremgangsmaatens utfoerelse.
DK374087A (da) Fremgangsmaade til fremstilling af proteiner med faktor viii-aktivitet ved hjaelp af mikrobielle voertsceller og ekspressionsvektorer, vaertsceller og antistoffer til anvendelse ved denne
NO964445L (no) DNA-sekvens, vektor, vertscelle og fremgangsmåte for transfeksjon av hematopoeseceller med eksogen DNA
NZ221790A (en) Method for the continuous production of a heterologous protein in a eukaryotic host cell
ATE158816T1 (de) Expression von pace in wirtszellen und verfahren zu dessen verwendung
DK158659C (da) 2,4,6-triiod-isophthalsyrederivater, deres fremstilling og roentgenkontrastmidler indeholdende disse.
AU587989B2 (en) DMA fragments, expression vectors, proteins, hosts, and process for production of the proteins
ZA864525B (en) Vector for expression of interferon-ypsilon in mammalian cells,method for using it and product obtained
NO179109C (no) Ekspresjonsvektor, rekombinante vertsceller samt fremgangsmåte for fremstilling av terapeutisk aktivt, rekombinant CSF
DK388789D0 (da) Hybridderivat af humant protein d, dets fremstilling og anvendelse samt dna, som koder derfor, og genstruktur og vaertscelle indeholdende denne dna
IT8520036A0 (it) Processo per la preparazione biotecnologica di acidi alfa-arilalcanoici otticamente attivi.
DK534286A (da) Nicotinsyrederivater, deres fremstilling og anvendelse som herbicider samt mellemprodukter ved fremstillingen og disses fremstilling
DK124787A (da) Peptider indeholdende op til 8-aminosyregrupperinger og fysiologisk uskadelige salte deraf, deres fremstilling og anvendelse som laegemidler samt mellemprodukter ved fremstillingen
DK354188D0 (da) Guanidinothiazolforbindelse, fremgangsmaade til d eres fremstilling samt anvendelsen heraf som mellemprodukt i famotidinprocessen
WO1994025590A3 (en) Trichohyalin and transglutaminase-3 and methods of using same
DK94385D0 (da) Proteiner, farmaceutiske praeparater, gener, vektorer, vaertsorganismer samt fremgangsmaader til deres fremstilling
NO874573D0 (no) Nucleinsyreprober for paavisning av latent humant cytomegalovirus i lodprodukter.
AU5945386A (en) Lymphotoxin dna, lymphotoxin expression vector, lymphotoxin resistant cell, transformant with lymphotoxin expression vector and process for preparing lymphotoxin
NO178036C (no) Fremgangsmåte for fremstilling av fusjonsproteiner, genstruktur, vektorer streptomycetceller og fusjonsproteinene
AU6521186A (en) Lytic viruses as expression vectors, host cell containing same and process for protein production

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees

Free format text: LAPSED IN APRIL 2003